Outcome of the Board Meeting and Submission of the Audited Standalone Financial Results for the Half year and year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shelter Pharma's board approved audited standalone financial results for FY25 (year ended March 31, 2025). Revenue from operations rose to Rs. 5,066.02 lakh from Rs. 4,002.29 lakh in FY24, a growth of about 26.6%. Profit after tax increased to Rs. 723.74 lakh from Rs. 620.02 lakh, while EPS rose to Rs. 6.26 from Rs. 5.36. The statutory auditor M/s. Mendajiwala & Co. issued an unmodified (clean) opinion on the results. The board also appointed M/s. I I Lakhani & Co. as internal auditor for FY 2025-26 and M/s. Murtuza Mandorwala & Associates as secretarial auditor for a five-year term (FY 2025-26 to FY 2029-30). Operating cash flow remained positive at Rs. 548.22 lakh, though cash and equivalents fell to Rs. 341.99 lakh due to investments in fixed assets.
Strong double-digit revenue growth along with higher profits reflects healthy business momentum and is positive for shareholders. The clean audit opinion and orderly auditor appointments support confidence in governance, though cash levels dipped due to capacity expansion.